Key result
A baseline TAPSE/PASP ratio <0.45 mm/mmHg was independently associated with increased all-cause mortality in CRT recipients (HR 1.437; 95% CI 1.145-1.805; P=0.002).
Why the study?
The evolution and prognostic values of echocardiographic RV-PA coupling in patients undergoing CRT had not been thoroughly investigated.
Does the TAPSE/PASP ratio predict all-cause mortality in patients undergoing cardiac resynchronization therapy?
Cohort (n=807)
Does the TAPSE/PASP ratio predict all-cause mortality in patients undergoing cardiac resynchronization therapy?
Hazard Ratio: 1.437 (95% CI 1.145–1.805)
p-value: p=0.002
Baseline TAPSE/PASP ratio <0.45 mm/mmHg and lack of improvement after CRT are independently associated with worse long-term survival in CRT recipients.
May refine post-CRT risk stratification; leaves open whether serial TAPSE/PASP should guide therapy.
AIMS: Chronic pressure overload and right ventricular (RV) dysfunction can lead to RV-pulmonary artery (PA) uncoupling in patients with heart failure. The evolution and prognostic values of RV-PA coupling assessed by echocardiography in patients undergoing cardiac resynchronization therapy (CRT) have not been thoroughly investigated. The aim of this study was to evaluate the evolution and prognostic value of tricuspid annular plane systolic excursion (TAPSE)/pulmonary artery systolic pressure (PASP) ratio in CRT recipients. METHODS AND RESULTS: The RV-PA coupling was measured non-invasively with echocardiography using the TAPSE/PASP ratio at baseline and 6 month follow-up in CRT recipients. The cut-off value for TAPSE/PASP uncoupling was derived from spline curve analysis (i.e. <0.45 mm/mmHg). The primary endpoint was all-cause mortality. A total of 807 patients (age 66 ± 11 years, 76% men) were analysed. During a median follow-up of 97 (54-143) months, 483 (60%) patients died. Survival rates at 3 and 5 year follow-up were significantly lower for patients with a TAPSE/PASP ratio <0.45 mm/mmHg (76% and 58%, respectively), compared with those with a TAPSE/PASP ratio ≥0.45 mm/mmHg (91% and 82%, respectively) (P < 0.001). On multivariable analysis, TAPSE/PASP ratio <0.45 mm/mmHg (hazard ratio 1.437; 95% confidence interval: 1.145-1.805; P = 0.002) was independently associated with all-cause mortality, whereas TAPSE <17 mm (hazard ratio 1.237; 95% confidence interval: 0.990-1.546; P = 0.061) was not. In addition, no improvement of the TAPSE/PASP ratio after CRT implantation was independently associated with worse survival. CONCLUSIONS: The TAPSE/PASP ratio at baseline is independently associated with long-term outcomes in CRT recipients. The baseline TAPSE/PASP ratio has incremental value over TAPSE, which does not take account of RV afterload. A lack of improvement in the TAPSE/PASP ratio after CRT implantation is associated with worse survival.
No takes yet. Share an insight, caveat, or question.
Stassen et al. (2022) conducted a cohort in Heart failure (n=807). TAPSE/PASP ratio <0.45 mm/mmHg vs. TAPSE/PASP ratio ≥0.45 mm/mmHg was evaluated on All-cause mortality (HR 1.437, 95% CI 1.145-1.805, p=0.002). A baseline TAPSE/PASP ratio <0.45 mm/mmHg was independently associated with increased all-cause mortality in CRT recipients (HR 1.437; 95% CI 1.145-1.805; P=0.002).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: